35.15
price down icon2.33%   -0.84
after-market After Hours: 35.00 -0.15 -0.43%
loading
Veracyte Inc stock is traded at $35.15, with a volume of 1.02M. It is down -2.33% in the last 24 hours and down -19.10% over the past month. Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
See More
Previous Close:
$35.99
Open:
$35.93
24h Volume:
1.02M
Relative Volume:
1.21
Market Cap:
$2.78B
Revenue:
$399.58M
Net Income/Loss:
$-54.04M
P/E Ratio:
-46.87
EPS:
-0.75
Net Cash Flow:
$40.13M
1W Performance:
+0.83%
1M Performance:
-19.10%
6M Performance:
+22.18%
1Y Performance:
-12.95%
1-Day Range:
Value
$34.17
$36.09
1-Week Range:
Value
$34.17
$37.57
52-Week Range:
Value
$22.61
$50.71

Veracyte Inc Stock (VCYT) Company Profile

Name
Name
Veracyte Inc
Name
Phone
(650) 243-6300
Name
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Name
Employee
824
Name
Twitter
@veracyte
Name
Next Earnings Date
2025-02-24
Name
Latest SEC Filings
Name
VCYT's Discussions on Twitter

Compare VCYT vs TMO, DHR, IDXX, A, WAT

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Diagnostics & Research icon
VCYT
Veracyte Inc
35.15 2.84B 399.58M -54.04M 40.13M -0.75
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
509.82 198.06B 44.56B 6.73B 6.29B 17.74
Diagnostics & Research icon
DHR
Danaher Corp
214.94 155.50B 24.57B 3.60B 5.25B 5.0475
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
617.20 51.80B 4.30B 1.06B 1.04B 13.08
Diagnostics & Research icon
A
Agilent Technologies Inc
124.88 36.46B 6.95B 1.30B 1.15B 4.5696
Diagnostics & Research icon
WAT
Waters Corp
319.83 32.29B 3.17B 642.63M 539.81M 10.77

Veracyte Inc Stock (VCYT) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-02-25 Resumed Morgan Stanley Underweight
Oct-20-25 Initiated Canaccord Genuity Hold
Mar-20-25 Initiated Craig Hallum Buy
Dec-05-24 Downgrade Goldman Buy → Neutral
Nov-15-24 Initiated Wolfe Research Outperform
Oct-16-24 Initiated UBS Buy
Oct-10-24 Initiated Guggenheim Buy
Feb-23-24 Reiterated Needham Buy
Jan-18-23 Downgrade Raymond James Outperform → Mkt Perform
Jan-05-23 Initiated Scotiabank Sector Outperform
Jan-07-22 Initiated Stephens Overweight
Nov-18-21 Resumed Goldman Buy
Jun-15-21 Initiated Raymond James Outperform
Feb-18-21 Resumed Needham Buy
Jan-28-21 Initiated Truist Buy
Nov-10-20 Initiated KeyBanc Capital Markets Sector Weight
Sep-09-20 Initiated Morgan Stanley Underweight
Jul-31-19 Initiated Lake Street Buy
Jul-02-19 Initiated Needham Buy
Nov-29-18 Downgrade Janney Buy → Neutral
Oct-31-18 Upgrade Janney Neutral → Buy
Nov-07-17 Downgrade Janney Buy → Neutral
Nov-07-17 Downgrade Piper Jaffray Overweight → Neutral
Aug-31-17 Resumed BTIG Research Buy
Nov-14-16 Resumed Leerink Partners Outperform
Dec-18-15 Initiated Cantor Fitzgerald Buy
Jun-11-15 Reiterated Leerink Partners Outperform
Nov-26-13 Initiated William Blair Outperform
View All

Veracyte Inc Stock (VCYT) Latest News

pulisher
Feb 12, 2026

56,756 Shares in Veracyte, Inc. $VCYT Bought by Thrivent Financial for Lutherans - MarketBeat

Feb 12, 2026
pulisher
Feb 11, 2026

Veracyte, Inc. $VCYT Stock Holdings Increased by Allianz Asset Management GmbH - MarketBeat

Feb 11, 2026
pulisher
Feb 10, 2026

Sentiment Watch: What are the future prospects of Veracyte Inc2025 Trading Volume Trends & Advanced Swing Trade Entry Plans - baoquankhu1.vn

Feb 10, 2026
pulisher
Feb 10, 2026

Is Veracyte (VCYT) Pricing Reflect Future Cash Flows After Multi Year Share Price Slide - Yahoo Finance

Feb 10, 2026
pulisher
Feb 10, 2026

Federated Hermes Inc. Sells 52,039 Shares of Veracyte, Inc. $VCYT - MarketBeat

Feb 10, 2026
pulisher
Feb 10, 2026

Principal Financial Group Inc. Boosts Stake in Veracyte, Inc. $VCYT - MarketBeat

Feb 10, 2026
pulisher
Feb 06, 2026

IQ EQ FUND MANAGEMENT IRELAND Ltd Has $4.78 Million Stock Holdings in Veracyte, Inc. $VCYT - MarketBeat

Feb 06, 2026
pulisher
Feb 05, 2026

Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT), Sarepta Therapeutics (SRPT) and Viridian Therapeutics (VRDN) - The Globe and Mail

Feb 05, 2026
pulisher
Feb 05, 2026

Veracyte (VCYT) Loses 20.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Finviz

Feb 05, 2026
pulisher
Feb 05, 2026

Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 - BioSpace

Feb 05, 2026
pulisher
Feb 04, 2026

Veracyte is Now Oversold (VCYT) - Nasdaq

Feb 04, 2026
pulisher
Feb 04, 2026

Here's Why Veracyte (VCYT) is a Strong Growth Stock - Yahoo Finance

Feb 04, 2026
pulisher
Feb 03, 2026

Aug Fed Impact: Can Veracyte Inc generate free cash flowJuly 2025 Earnings & Safe Investment Capital Preservation Plans - baoquankhu1.vn

Feb 03, 2026
pulisher
Feb 03, 2026

Veracyte’s Growth Story Hit A Valuation Wall - Finimize

Feb 03, 2026
pulisher
Feb 03, 2026

Veracyte, Inc. (NASDAQ:VCYT) Receives Average Rating of "Hold" from Analysts - MarketBeat

Feb 03, 2026
pulisher
Feb 03, 2026

Stock Report: Is Veracyte Inc stock a top performer YTD2025 Price Targets & Expert Approved Momentum Trade Ideas - baoquankhu1.vn

Feb 03, 2026
pulisher
Feb 02, 2026

Improved Revenues Required Before Veracyte, Inc. (NASDAQ:VCYT) Shares Find Their Feet - 富途牛牛

Feb 02, 2026
pulisher
Feb 02, 2026

Targets Report: What makes Veracyte Inc. stock attractive today2025 Major Catalysts & AI Powered Trade Plan Recommendations - baoquankhu1.vn

Feb 02, 2026
pulisher
Jan 30, 2026

GRAIL Submits FDA PMA for Galleri Multi-Cancer Early Detection Test - Nasdaq

Jan 30, 2026
pulisher
Jan 30, 2026

Here's Why Veracyte (VCYT) Is a Great 'Buy the Bottom' Stock Now - Finviz

Jan 30, 2026
pulisher
Jan 29, 2026

Reasons to Retain Avanos Medical Stock in Your Portfolio Now - Finviz

Jan 29, 2026
pulisher
Jan 28, 2026

Can Veracyte Inc. ride the EV waveQuarterly Portfolio Report & Precise Buy Zone Identification - mfd.ru

Jan 28, 2026
pulisher
Jan 28, 2026

Earnings Miss: Can Veracyte Inc expand into new marketsEarnings Summary Report & Fast Moving Market Watchlists - baoquankhu1.vn

Jan 28, 2026
pulisher
Jan 27, 2026

Veracyte, Inc. (VCYT) Stock Analysis: A Diagnostic Leader With 17.49% Potential Upside - DirectorsTalk Interviews

Jan 27, 2026
pulisher
Jan 27, 2026

Why Veracyte (VCYT) is poised to beat earnings estimates again - MSN

Jan 27, 2026
pulisher
Jan 26, 2026

Veracyte, Inc. (VCYT) sees analyst support as Guggenheim reaffirms buy rating - MSN

Jan 26, 2026
pulisher
Jan 26, 2026

Why Veracyte (VCYT) is Poised to Beat Earnings Estimates Again - Prime Publishers, Inc.

Jan 26, 2026
pulisher
Jan 26, 2026

If You Invested $1000 in Veracyte a Decade Ago, This is How Much It'd Be Worth Now - MSN

Jan 26, 2026
pulisher
Jan 26, 2026

Veracyte Inc. (NASDAQ:VCYT) Emerges as a Prime Affordable Growth Candidate - Chartmill

Jan 26, 2026
pulisher
Jan 26, 2026

AEGON ASSET MANAGEMENT UK Plc Has $14.06 Million Stock Position in Veracyte, Inc. $VCYT - MarketBeat

Jan 26, 2026
pulisher
Jan 24, 2026

Stronger‑Than‑Expected Revenue Outlook Might Change The Case For Investing In Veracyte (VCYT) - simplywall.st

Jan 24, 2026
pulisher
Jan 22, 2026

Swing Trade: What is the dividend yield of TriSalus Life Sciences Inc Equity WarrantJuly 2025 WrapUp & Verified Entry Point Signals - baoquankhu1.vn

Jan 22, 2026
pulisher
Jan 22, 2026

Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term - Yahoo Finance

Jan 22, 2026
pulisher
Jan 22, 2026

Assessing Veracyte (VCYT) Valuation As Recent Momentum Meets An Expensive P/E Ratio - Sahm

Jan 22, 2026
pulisher
Jan 22, 2026

Is Veracyte’s (VCYT) Confident Double‑Digit Revenue Outlook Altering The Investment Case For Investors? - Yahoo Finance

Jan 22, 2026
pulisher
Jan 22, 2026

Veracyte, Inc. (VCYT) Sees Analyst Support as Guggenheim Reaffirms Buy Rating - Finviz

Jan 22, 2026
pulisher
Jan 21, 2026

Centene Expands Palliative Care Access in Ohio Through Tuesday Health - Nasdaq

Jan 21, 2026
pulisher
Jan 21, 2026

QRG Capital Management Inc. Sells 106,926 Shares of Veracyte, Inc. $VCYT - MarketBeat

Jan 21, 2026
pulisher
Jan 18, 2026

S P Trends: Is Veracyte Inc showing insider buyingTrade Entry Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn

Jan 18, 2026
pulisher
Jan 17, 2026

State of Alaska Department of Revenue Takes $1.50 Million Position in Veracyte, Inc. $VCYT - MarketBeat

Jan 17, 2026
pulisher
Jan 16, 2026

Trade Recap: Is Veracyte Inc stock a value trapJuly 2025 PostEarnings & Risk Managed Trade Strategies - baoquankhu1.vn

Jan 16, 2026
pulisher
Jan 16, 2026

Veracyte: Profitable, De-Risked, And Ready To Run (NASDAQ:VCYT) - Seeking Alpha

Jan 16, 2026
pulisher
Jan 16, 2026

Sumitomo Mitsui Trust Group Inc. Sells 165,094 Shares of Veracyte, Inc. $VCYT - MarketBeat

Jan 16, 2026
pulisher
Jan 16, 2026

SG Americas Securities LLC Increases Stock Position in Veracyte, Inc. $VCYT - MarketBeat

Jan 16, 2026
pulisher
Jan 15, 2026

Veracyte (NASDAQ:VCYT) Cut to Hold at Zacks Research - MarketBeat

Jan 15, 2026
pulisher
Jan 14, 2026

Is Veracyte’s 2026 Growth Guidance And New US Launches Altering The Investment Case For Veracyte (VCYT)? - Sahm

Jan 14, 2026
pulisher
Jan 14, 2026

Louisiana State Employees Retirement System Invests $1.24 Million in Veracyte, Inc. $VCYT - MarketBeat

Jan 14, 2026
pulisher
Jan 14, 2026

Lung Cancer Diagnostics Market Size and Forecast 2025–2033 - Vocal

Jan 14, 2026
pulisher
Jan 13, 2026

Breakout Move: What is the dividend yield of CMMBJuly 2025 Patterns & AI Optimized Trade Strategies - baoquankhu1.vn

Jan 13, 2026
pulisher
Jan 13, 2026

Volume Recap: Is Veracyte Inc. stock a top pick in earnings seasonStock Surge & Accurate Trade Setup Notifications - Bộ Nội Vụ

Jan 13, 2026

Veracyte Inc Stock (VCYT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
diagnostics_research DGX
$206.86
price down icon 1.18%
diagnostics_research LH
$278.11
price down icon 4.06%
diagnostics_research MTD
$1,357.92
price down icon 2.49%
diagnostics_research IQV
$168.85
price down icon 4.70%
$207.84
price down icon 2.18%
diagnostics_research WAT
$319.83
price down icon 2.85%
Cap:     |  Volume (24h):